生物制药巨头安进公司近日向监管机构提交了Cbe-30类别文件，对其产品标签中的肝毒性警告内容进行了重要修订。此次更新特别针对与Tavneos（avacopan）相关的血管炎病例信息披露进行了强化，在原有警示基础上补充了更具临床参考价值的病例数据。
修订后的标签语言不仅完善了对潜在肝毒性风险的描述，还通过详实的临床案例为医疗专业人员提供了更全面的用药指导。这一调整体现了安进对药物安全监测的持续重视，旨在帮助医生更准确地评估用药风险收益比。
此次标签更新基于最新的药物安全性监测数据，反映了安进对产品安全信息的及时更新承诺。公司表示将继续密切监测Tavneos在真实世界应用中的安全性表现，确保患者用药安全。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.